Top

Published in:

Open Access 01-12-2015 | Review

Tetracyclines in malaria

Authors: Tiphaine Gaillard, Marylin Madamet, Bruno Pradines

Published in: Malaria Journal | Issue 1/2015

Abstract

Malaria, a parasite vector-borne disease, is one of the greatest health threats in tropical regions, despite the availability of malaria chemoprophylaxis. The emergence and rapid extension of Plasmodium falciparum resistance to various anti-malarial drugs has gradually limited the number of potential malaria therapeutics available to clinicians. In this context, doxycycline, a synthetically derived tetracycline, constitutes an interesting alternative for malaria treatment and prophylaxis. Doxycycline is a slow-acting blood schizontocidal agent that is highly effective at preventing malaria. In areas with chloroquine and multidrug-resistant P. falciparum parasites, doxycycline has already been successfully used in combination with quinine to treat malaria, and it has been proven to be effective and well-tolerated. Although not recommended for pregnant women and children younger than 8 years of age, severe adverse effects are rarely reported. In addition, resistance to doxycycline is rarely described. Prophylactic and clinical failures of doxycycline have been associated with both inadequate doses and poor patient compliance. The effects of tetracyclines on parasites are not completely understood. A better comprehension of the mechanisms underlying drug resistance would facilitate the identification of molecular markers of resistance to predict and survey the emergence of resistance.

Tan KR, Magill AJ, Parise ME, Arguin PM. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2011;84:517–31.PubMedCentralPubMed

Gialdroni Grassi G. Tetracyclines-extending the atypical spectrum. Int J Antimicrob Agents. 1993;3:31–46.

Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit. 1982;4:115–35.PubMed

Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–66.PubMed

Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother. 1977;11:462–9.PubMedCentralPubMed

Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411–7.PubMed

Newton PN, Chaulet J-F, Brockman A, Chierakul W, Dondorp A, Ruangveerayuth R, et al. Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrob Agents Chemother. 2005;49:1622–5.PubMedCentralPubMed

Driscoll MS, Rothe MJ, Abrahamian L, Grant-Kels JM. Long-term oral antibiotics for acne: is laboratory monitoring necessary? J Am Acad Dermatol. 1993;28:595–602.PubMed

Delaney TJ, Leppard BJ, MacDonald DM. Effects of long term treatment with tetracycline. Acta Derm Venereol. 1974;54:487–9.PubMed

10.

Sánchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet. 1993;341:1021–2.PubMed

11.

Shamiss A, Atar E, Zohar L, Cain Y. Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Aviat Space Environ Med. 1996;67:872–3.PubMed

12.

Wallace MR, Sharp TW, Smoak B, Iriye C, Rozmajzl P, Thornton SA, et al. Malaria among United States troops in Somalia. Am J Med. 1996;100:49–55.PubMed

13.

Conrad KA, Kiser WR. Doxycycline vs. mefloquine. Mil Med. 1997;162:viii.PubMed

14.

Korhonen C, Peterson K, Bruder C, Jung P. Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers. Am J Prev Med. 2007;33:194–9.PubMed

15.

Baudon D, Martet G, Pascal B, Bernard J, Keundjian A, Laroche R. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army. Trans R Soc Trop Med Hyg. 1999;93:302–3.PubMed

16.

Malmborg AS. Bioavailability of doxycycline monohydrate. A comparison with equivalent doses of doxycycline hydrochloride. Chemother. 1984;30:76–80.

17.

Pages F, Boutin JP, Meynard JB, Keundjian A, Ryfer S, Giurato L, et al. Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. Trop Med Int Health. 2002;7:919–24.PubMed

18.

Kichener SJ, Nasveld PE, Gregory RM, Edstein MD. Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust. 2005;182:168–71.

19.

Sonmez A, Harlak A, Kilic S, Polat Z, Hayat L, Keskin O, et al. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect. 2005;51:253–8.PubMed

20.

Schlagenfauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, for arm study. BMJ. 2003;327:1–6.

21.

Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65:232–60.PubMedCentralPubMed

22.

Taylor DN, Pitarangsi C, Echeverria P, Diniega BM. Campylobacter enteritis during doxycycline prophylaxis for malaria in Thailand. Lancet. 1988;2:578–9.PubMed

23.

Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg. 1990;43:608–13.PubMed

24.

Vento TJ, Cole DW, Mende K, Calvano TP, Rini EA, Tully C, et al. Multidrug-resistant fram-negative bacteria colonization of healthy US military personnel in the US and Afghanistan. BMC Infect Dis. 2013;13:68.PubMedCentralPubMed

25.

Vento TJ, Cole DW, Mende K, Calvano TP, Rini EA, Tully C, et al. Staphylococcus aureus colonization of healthy military service members in the United States and Afghanistan. BMC Infect Dis. 2013;13:325.PubMedCentralPubMed

26.

Lesens O, Haus-Cheymol R, Dubrous P, Verret C, Spiegel A, Bonnet R, et al. Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, Côte d’Ivoire. Emerg Infect Dis. 2007;13:488–90.PubMedCentralPubMed

27.

Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19:1–24.PubMed

28.

Sharma I, Sullivan M, McCutchan TF. The in vitro anti-malarial activity of novel semi synthetic nocathiacin I antibiotics. Antimicrob Agents Chemother. 2015;59:3174–9.PubMed

29.

Blum JJ, Yayon A, Friedman S, Ginsburg H. Effects of mitochondrial protein synthesis inhibitors on the incorporation of isoleucine into Plasmodium falciparum in vitro. J Protozool. 1984;31:475–9.PubMed

30.

Kiatfuengfoo R, Suthiphongchai T, Prapunwattana P, Yuthavong Y. Mitochondria as the site of action of tetracycline on Plasmodium falciparum. Mol Biochem Parasitol. 1989;34:109–15.PubMed

31.

Budimulja AS, Syafruddin, Tapchaisri P, Wilairat P, Marzuki S. The sensitivity of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors. Mol Biochem Parasitol. 1997;84:137–41.PubMed

32.

Prapunwattana P, O’Sullivan WJ, Yuthavong Y. Depression of Plasmodium falciparum dihydroorotate dehydrogenase activity in in vitro culture by tetracycline. Mol Biochem Parasitol. 1988;27:119–24.PubMed

33.

Yeo AE, Edstein MD, Shanks GD, Rieckmann KH. Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro. Parasitol Res. 1997;83:489–91.PubMed

34.

Lin Q, Katakura K, Suzuki M. Inhibition of mitochondrial and plastid activity of Plasmodium falciparum by minocycline. FEBS Lett. 2002;515:71–4.PubMed

35.

Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50:3124–31.PubMedCentralPubMed

36.

Yeh E, DeRisi JL. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol. 2011;9:1001138.

37.

Briolant S, Almeras L, Belghazi M, Boucomont-Chapeaublanc E, Wurtz N, Fontaine A, et al. Plasmodium falciparum proteome changes in response to doxycycline treatment. Malar J. 2010;9:141.PubMedCentralPubMed

38.

Ruiz Sanchez F, Casillas J, Paredes M, Lelazquez J, Riebeling QB. Terramycin in malaria therapy. Pan Am Med Womans J. 1952;59:10–5.PubMed

39.

Grande EN, Sanchez AR, Sanchez FR. The treatment of malaria with tetracycline. Antibiotic Med Clin Ther. 1956;3:193–6.

40.

Clyde DF, Miller RM, DuPont HL, Hornick RB. Antimalarial effects of tetracyclines in man. J Trop Med Hyg. 1971;74:238–42.PubMed

41.

Willerson D Jr, Rieckmann KH, Carson PE, Frischer H. Effects of minocycline against chloroquine-resistant falciparum malaria. Am J Trop Med Hyg. 1972;21:857–62.PubMed

42.

Garnham PC, Warren M, Killick-Kendrick R. The action of ‘terramycin’ on the primary exoerythrocytic development of Plasmodium vivax and Plasmodium cynomolgi ceylonensis. J Trop Med Hyg. 1971;74:2–35.

43.

Kumar A, Dutta GP. Tissue schizontocidal activity of minocycline against a relapsing malaria parasite Plasmodium cynomolgi B. Indian J Med Res. 1987;85:519–21.PubMed

44.

Kumar A, Dutta GP. Antimalarial activity of demeclocycline against Plasmodium cynomolgi bastianellii in rhesus monkeys. Ann Trop Med Parasitol. 1989;83:199–206.PubMed

45.

Marussig M, Motard A, Renia L, Baccam D, Lebras J, Charmot G, Mazier D. Activity of doxycycline against preerythrocytic malaria. J Infect Dis. 1993;168:1603–4.PubMed

46.

Shmuklarsky MJ, Boudreau EF, Pang LW, Smith JI, Schneider I, Fleckenstein L, et al. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Intern Med. 1994;120:294–9.PubMed

47.

Rieckmann KH, Yeo AE, Davis DR, Hutton DC, Wheatley PF, Simpson R. Recent military experience with malaria chemoprophylaxis. Med J Aust. 1993;158:446–9.PubMed

48.

Orlandi-Pradines E, Penhoat K, Durand C, Pons C, Bay C, Pradines B, et al. Antibody responses to several malaria pre-erythrocytic antigens as a marker of malaria exposure among travelers. Am J Trop Med Hyg. 2006;74:979–85.PubMed

49.

Geary TG, Divo AA, Jensen JB. Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Am J Trop Med Hyg. 1989;40:240–4.PubMed

50.

Legrand E, Volney B, Meynard J-B, Mercereau-Puijalon O, Esterre P. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother. 2008;52:288–98.PubMedCentralPubMed

51.

Briolant S, Wurtz N, Zettor A, Rogier C, Pradines B. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis. 2010;201:153–9.PubMed

52.

Pradines B, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, et al. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. Am J Trop Med Hyg. 2000;62:82–5.PubMed

53.

Pradines B, Rogier C, Fusai T, Mosnier J, Daries W, Barret E, et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob Agents Chemother. 2001;45:1746–50.PubMedCentralPubMed

54.

Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987;i:1161–4.

55.

Pang L, Limsomwong N, Singharaj P. Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline. J Infect Dis. 1988;158:1124–7.PubMed

56.

Watanasook C, Singharaj P, Suriyamongkol V, Karwacki JJ, Shanks D, Phintuyothin P, et al. Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border. Southeast Asian J Trop Med Public Health. 1989;20:61–4.PubMed

57.

Shanks GD, Edstein MD, Suriyamongkol V, Timsaad S, Webster HK. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg. 1992;46:643–8.PubMed

58.

Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999;28:74–81.PubMed

59.

Shanks GD, Barnett A, Edstein MD, Rieckmann KH. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Med J Aust. 1995;162:306–7.PubMed

60.

Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis. 1995;171:1569–75.PubMed

61.

Migliani R, Josse R, Hovette R, Keundjian A, Pagès F, Meynard JB, et al. Le paludisme vu des tranchées: le cas de la Côte d’Ivoire en 2002–2003. Med Trop. (Mars). 2003;63:282–6.

62.

Migliani R, Ollivier L, Romand O, Verret C, Haus-Cheymol R, Todesco A, et al. Paludisme chez les militaires français en Côte d’Ivoire de 1998 à 2006. Bull Epidemiol Hebdom. 2008;23–24:209–12.

63.

Shanks GD, Roessler P, Edstein M, Rieckmann KH. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med. 1995;160:443–4.PubMed

64.

Madamet M, Gaillard T, Velut G, Ficko C, Houzé P, Bilicky C, et al. Malaria prophylaxis failure with doxycycline, Central African Republique, 2014. Emerg Infect Dis. 2015;21:1485–6.PubMedCentralPubMed

65.

Pukrittayakamee S, Clemens R, Chantra A, Nontprasert A, Luknam T, Looareesuwan S, et al. Therapeutic responses to antibacterial drugs in vivax malaria. Trans R Soc Trop Med Hyg. 2001;95:524–8.PubMed

66.

Rieckmann KH, Powell RD, McNamara JV, Willerson D Jr, Lass L, Frischer H, et al. Effects of tetracycline against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum. Am J Trop Med Hyg. 1971;20:811–5.PubMed

67.

Laing AB. The effect of tetracycline on Plasmodium falciparum in the Gambia. Trans R Soc Trop Med Hyg. 1972;66:956–7.PubMed

68.

Ponnampalam JT. Doxycycline in the treatment of falciparum malaria among aborigine children in West Malaysia. Trans R Soc Trop Med Hyg. 1981;75:372–7.PubMed

69.

Chin W, Intraprasert R. The evaluation of quinine alone or in combination with tetracycline and pyrimethamine against falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 1973;4:245–9.PubMed

70.

Colwell EJ, Hickman RL, Kosakal S. Quinine-tetracycline and quinine-bactrim treatment of acute falciparum malaria in Thailand. Ann Trop Med Parasitol. 1973;67:125–32.PubMed

71.

Noeypatimanond S, Malikul S, Benjapong W, Duriyananda D, Ungkasrithongkul M. Treatment of Plasmodium falciparum malaria with a combination of amodiaquine and tetracycline in Central Thailand. Trans R Soc Trop Med Hyg. 1983;77:338–40.PubMed

72.

Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother. 2004;48:1329–34.PubMedCentralPubMed

73.

Alecrim MG, Lacerda MV, Mourão MP, Alecrim WD, Padilha A, Cardoso BS, et al. Successful treatment of Plasmodium falciparum malaria with a six-dose regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon region of Brazil. Am J Trop Med Hyg. 2006;74:20–5.PubMed

74.

Watt G, Loesuttivibool L, Shanks GD, Boudreau EF, Brown AE, Pavanand K, et al. Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg. 1992;47:108–11.PubMed

75.

Jacobs RL, Koontz LC. Plasmodium berghei: development of resistance to clindamycin and minocycline in mice. Exp Parasitol. 1976;40:116–23.PubMed

76.

Divo AA, Geary TG, Jensen JB. Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture. Antimicrob Agents Chemother. 1985;27:21–7.PubMedCentralPubMed

77.

Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, et al. Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Malar J. 2011;10:8.PubMedCentralPubMed

78.

Fall B, Pascual A, Sarr FD, Wurtz N, Richard V, Baret E, et al. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J. 2013;12:107.PubMedCentralPubMed

79.

Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, et al. Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother. 2009;53:688–95.PubMedCentralPubMed

80.

Gaillard T, Briolant S, Houzé S, Baragatti M, Wurtz N, Hubert V, et al. PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. Malar J. 2013;12:414.PubMedCentralPubMed

81.

Gaillard T, Fall B, Tall A, Wurtz N, Diatta B, Lavina M, et al. Absence of association between ex vivo susceptibility to doxycycline and pftetQ and pfmdt copy numbers in Plasmodium falciparum isolates from Dakar. Senegal. Clin Microbiol Infect. 2012;18:238–40.

82.

Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, et al. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J. 2011;10:310.PubMedCentralPubMed

83.

Achieng AO, Ingasia LA, Juma DW, Cheruiyot AC, Okudo CA, Yeda RA, et al. Reduced in vitro doxycycline susceptibility in Plasmodium falciparum field isolates from Kenya is associated with PfTetQ KYNNNN sequence polymorphism. Antimicrob Agents Chemother. 2014;58:5894–9.PubMedCentralPubMed

84.

Gaillard T, Sriprawat K, Briolant S, Wangsing C, Wurtz N, Baragatti M, et al. Molecular markers and in vitro susceptibility to doxycycline in Plasmodium falciparum isolates from Thailand. Antimicrob Agents Chemother. 2015;59:5080–3.PubMed

85.

Quashie NB, Duah NO, Abuaku B, Quaye L, Ayanful-Torgby R, Akwoviah GA, et al. A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs. Malar J. 2013;12:450.PubMedCentralPubMed

86.

Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, et al. Reliability of antimalarial sensitivity tests depends on drug mechanism of action. J Clin Microbiol. 2010;48:1651–60.PubMedCentralPubMed

87.

Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev. 1996;60:575–608.PubMedCentralPubMed

88.

Yang W, Moore IF, Koteva KP, Bareich DC, Hughes DW, Wright GD. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem. 2004;279:52346–52.PubMed

89.

Dantley KA, Dannelly HK, Burdett V. Binding interaction between Tet(M) and the ribosome: requirements for binding. J Bacteriol. 1998;180:4089–92.PubMedCentralPubMed

90.

Trieber CA, Burkhardt N, Nierhaus KH, Taylor DE. Ribosomal protection from tetracycline mediated by Tet(O): Tet(O) interaction with ribosomes is GTP-dependent. Biol Chem. 1998;379:847–55.PubMed

91.

Briolant S, Fusai T, Rogier C, Pradines B. Tetracycline antibiotics in malaria. Open Trop Med J. 2008;1:31–46.

92.

Mura M, Briolant S, Donato D, Volney B, Pelleau S, Musset LA, et al. Absence of correlation between ex vivo susceptibility to doxycycline and pfteQ-pfmdt gene polymorphism in French Guiana. Malar J. 2015;14:286.PubMedCentralPubMed

93.

Gaillard T, Wurtz N, Houzé S, Sriprawat K, Wangsing C, Hubert V, et al. Absence of association between Plasmodium falciparum small sub-unit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline. Malar J. 2015;14:348.PubMedCentralPubMed

94.

Gerrits MM, de Zoete MR, Arents NLA, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2996–3000.PubMedCentralPubMed

95.

Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol. 2002;184:2131–40.PubMedCentralPubMed

96.

Ross JI, Eady EA, Cove JH, Cunliffe WJ. 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998;42:1702–5.PubMedCentralPubMed

97.

Dailidiene D, Bertoli MT, Miciuleviciene J, Mukhopadhyay AK, Dailide G, Pascasio MA, et al. Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother. 2002;46:3940–6.PubMedCentralPubMed

98.

Ribeiro ML, Gerrits MM, Benvengo YHB, Berning M, Godoy APO, Kuipers EJ, et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol. 2004;40:57–61.PubMed

99.

Wilson RJ, Denny PW, Preiser PR, Rangachari K, Roberts K, Roy A, et al. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J Mol Biol. 1996;261:155–72.PubMed

100.

Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013;45:648–55.PubMed

101.

Ménard S, Ben Haddou T, Ramadani AP, Ariey F, Iriart X, Beghain J, et al. Induction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressure. Emerg Infect Dis. 2015;21:1733–41.PubMedCentralPubMed

102.

Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.PubMed

103.

Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:963–72.PubMed

104.

Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis. 1998;26:146–50.PubMed

105.

Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for nonimmune travelers: a comparison with mefloquine and doxycycline. Clin Infect Dis. 1999;29:1502–6.PubMed

106.

Peragallo MS, Croft AM, Kitchener SJ. Malaria during a multinational military deployment: the comparative experience of the Italian, British and Australian Armed Forces in East Timor. Trans R Soc Trop Med Hyg. 2002;96:481–2.PubMed

107.

Clyde DF, Miller RM, Music SI, McCarthy VC. Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Vietnam. Am J Trop Med Hyg. 1971;20:1–5.PubMed

108.

Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra, et al. Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg. 2001;64:223–8.PubMed

109.

Colwell EJ, Hickman RL, Kosakal S. Tetracycline treatment of chloroquine-resistant falciparum malaria in Thailand. JAMA. 1972;220:684–6.PubMed

110.

Giboda M, Denis MB. Response of Kampuchean strains of Plasmodium falciparum to antimalarials: in vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro. J Trop Med Hyg. 1988;91:205–11.PubMed

111.

Looareesuwan S, Vanijanonta S, Viravan C, Wilairatana P, Charoenlarp P, Lasserre R, et al. Randomised trial of mefloquine-tetracycline and quinine-tetracycline for acute uncomplicated falciparum malaria. Acta Trop. 1994;57:47–53.PubMed

112.

Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Charoenlarp P, Canfield CJ, et al. Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria. Am J Trop Med Hyg. 1994;50:784–9.PubMed

113.

Metzger W, Mordmüller B, Graninger W, Bienzle U, Kremsner PG. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother. 1995;36:723–8.PubMed

114.

Na-Bangchang K, Kanda T, Tipawangso P, Thanavibul A, Suprakob K, Ibrahim M, et al. Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. Southeast Asian J Trop Med Public Health. 1996;27:522–5.PubMed

115.

Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996;54:62–6.PubMed

116.

Duarte EC, Fontes CJ, Gyorkos TW, Abrahamowicz M. Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Am J Trop Med Hyg. 1996;54:197–202.PubMed

117.

Bunnag D, Karbwang J, Na-Bangchang K, Thanavibul A, Chittamas S, Harinasuta T. Quinine-tetracycline for multidrug resistant falciparum malaria. Southeast Asian J Trop Med Public Health. 1996;27:15–8.PubMed

118.

Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 2000;44:2395–8.PubMedCentralPubMed

119.

Ejaz A, Haqnawaz K, Hussain Z, Butt R, Awan ZI, Bux H. Treatment of uncomplicated plasmodium falciparum malaria with quinine-doxycycline combination therapy. J Pak Med Assoc. 2007;57:502–5.PubMed

Title: Tetracyclines in malaria
Authors: Tiphaine Gaillard
Marylin Madamet
Bruno Pradines
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/s12936-015-0980-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Tetracyclines in malaria

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Factors affecting delay in seeking treatment among malaria patients along Thailand-Myanmar border in Tak Province, Thailand

Asymptomatic Plasmodium falciparum infections may not be shortened by acquired immunity

Administration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria

Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar

‘A bite before bed’: exposure to malaria vectors outside the times of net use in the highlands of western Kenya

Attenuation of Plasmodium falciparum in vitro drug resistance phenotype following culture adaptation compared to fresh clinical isolates in Cambodia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page